Sun Pharma Advanced Research Co (NSE:SPARC) Growth Rank: 3 (As of Aug. 30, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
53 GF Score
Price ₹207.71
GF Value ₹4,379.05
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co Growth Rank?

Sun Pharma Advanced Research Co NSE:SPARC +6.53% 53 Growth Rank is 3 as of Aug. 30, 2026, which is at its 10-year median of 3.00. GuruFocus rates NSE:SPARC with a GF Score™ of 53/100 and a GF Value™ of ₹4,379.05 (Possible Value Trap). The stock has 4 warning signs investors should review.

Sun Pharma Advanced Research Co has the Growth Rank of 3.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Sun Pharma Advanced Research Co Growth Rank Related Terms

NSE:SPARC vs ZTS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sun Pharma Advanced Research Co Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's Growth Rank distribution charts can be found below:

* The bar in red indicates where Sun Pharma Advanced Research Co's Growth Rank falls into.


NSE:SPARC
53GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 3 mean?
Sun Pharma Advanced Research Co (NSE:SPARC) has a Growth Rank of 3 as of Aug. 30, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sun Pharma Advanced Research Co and its competitors. This is near median its historical median of 3.00. Over the past decade, Sun Pharma Advanced Research Co's Growth Rank has ranged from 1.00 to 7.00.
Is Sun Pharma Advanced Research Co's Growth Rank too high?
Sun Pharma Advanced Research Co's current Growth Rank of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Growth Rank compare to ZTS?
Sun Pharma Advanced Research Co's Growth Rank of 3 can be compared against companies in the Drug Manufacturers industry. Historically, Sun Pharma Advanced Research Co's own Growth Rank has ranged from 1.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sun Pharma Advanced Research Co and its competitors. Sun Pharma Advanced Research Co's current Growth Rank is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,379.05, compared to a current price of ₹207.71 — trading 95.3% below its estimated fair value. The current Growth Rank is 3, which is near median its 10-year median of 3.00. Sun Pharma Advanced Research Co's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current Growth Rank is 3 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued. The current stock price of ₹207.71 is trading 95.3% below its estimated GF Value™ of ₹4,379.05. GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.

Key valuation signals for NSE:SPARC:

  • Growth Rank: 3 (near median its 10-year median of 3.00)
  • GF Value™: ₹4,379.05 vs. price of ₹207.71 (95.3% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
53GF Score

Get the complete analysis for NSE:SPARC

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹207.71
Price
₹4,379.05
GF Value